論文 - 詳細
| RRC ID | 52415 |
|---|---|
| 著者 | Ji B, Guo W, Ma H, Xu B, Mu W, Zhang Z, Amat A, Cao L. |
| タイトル | Isoliquiritigenin suppresses IL-1β induced apoptosis and inflammation in chondrocyte-like ATDC5 cells by inhibiting NF-κB and exerts chondroprotective effects on a mouse model of anterior cruciate ligament transection. |
| ジャーナル | Int J Mol Med |
| Abstract |
Isoliquiritigenin (ISL), a natural flavonoid extracted from licorice, has been demonstrated to exert attenuation of the nuclear factor-κB (NF-κB) signaling pathway and anti-inflammatory activity in a wide variety of cells. In the present study, the authors first evaluated the effects of ISL on cartilage degeneration in interleukin-1β (IL-1β)-stimulated chondrocyte-like ATDC5 cells and in a mouse model of osteoarthritis (OA). The data of a cell counting kit-8 and flow cytometry assay indicated that ISL suppressed the inhibitory effect of IL-1β on cell viability. The mRNA and protein expression levels of cyclooxygenase-2 and matrix metalloproteinase-13 were significantly decreased, while the expression of collagen II was increased, as indicated by RT-qPCR and western blot analysis following the chondrocyte-like ATDC5 cells were co-intervened with IL-1β and ISL for 48 h. Also, ISL attenuated protein expressions level of pro-apoptotic Bax, cleaved-caspase-3 and cleaved-caspase-9 and promoted expression of anti-apoptotic Bcl-2. Moreover, ISL inhibited NF-κB p65 phosphorylation induced by IL-1β. In addition, ISL also increased improved the thickness of hyaline cartilage and the production of proteoglycans in the cartilage matrix in a mouse OA model. These results indicated that ISL exerted anti-inflammatory and anti-apoptotic effects on IL-1β-stimulated chondrocyte-like ATDC5 cells, which may be associated with the downregulation of the NF-κB signaling pathway. In this way, the data supported the conclusion that ISL may be a novel potential preventive agent suitable for use in OA therapy. |
| 巻・号 | 40(6) |
| ページ | 1709-1718 |
| 公開日 | 2017-12-1 |
| DOI | 10.3892/ijmm.2017.3177 |
| PMID | 29039445 |
| PMC | PMC5716454 |
| MeSH | Animals Anterior Cruciate Ligament / metabolism Anti-Inflammatory Agents / pharmacology* Apoptosis / drug effects* Cell Line Chalcones / pharmacology* Chondrocytes / metabolism* Disease Models, Animal Inflammation / metabolism Interleukin-1beta / metabolism* Male Mice Mice, Inbred C57BL NF-kappa B / antagonists & inhibitors* Osteoarthritis / metabolism Protective Agents / pharmacology* |
| IF | 3.098 |
| 引用数 | 21 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 2 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | ATDC5(RCB0565) |